Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Pyoderma Gangrenosum
NCT07767864Phase 2Not yet recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of bimekizumab in pyoderma gangrenosum (PG), sponsored by Oregon Health & Science University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT07767864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767864.